Workflow
润都股份(002923) - 2024 Q3 - 季度财报
Rundu PharmaRundu Pharma(SZ:002923)2024-10-28 10:56

Financial Performance - The company's revenue for Q3 2024 was ¥279,820,741.98, a decrease of 3.49% compared to the same period last year[2]. - Total operating revenue for Q3 2024 was CNY 876,987,074.94, a decrease of 7.2% compared to CNY 945,364,659.04 in Q3 2023[10]. - Net profit for Q3 2024 was CNY 37,180,512.39, a decline of 43.3% from CNY 65,557,927.00 in Q3 2023[11]. - The net profit attributable to shareholders was -¥620,955.51, representing an increase of 83.19% year-on-year[2]. - The total comprehensive income attributable to the parent company for Q3 2024 is CNY 37,180,516.39, compared to CNY 65,558,528.36 in the previous period, reflecting a decrease of approximately 43.3%[12]. - Basic and diluted earnings per share for Q3 2024 are both CNY 0.11, down from CNY 0.20 in the same period last year, representing a decline of 45%[12]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,165,656,588.52, down 2.79% from the end of the previous year[2]. - Total assets decreased to CNY 2,165,656,588.52 in Q3 2024 from CNY 2,227,773,648.98 in Q3 2023, showing a contraction in the asset base[9]. - Total liabilities decreased to CNY 1,016,252,920.91 in Q3 2024 from CNY 1,048,614,189.72 in Q3 2023, reflecting improved financial management[9]. - Non-current liabilities totaled CNY 575,838,112.98, down from CNY 602,302,627.95 in the previous year, indicating a reduction in long-term debt[9]. - The equity attributable to shareholders was ¥1,149,403,667.61, a decrease of 2.52% from the previous year[2]. - The company's equity attributable to shareholders decreased to CNY 1,149,403,667.61 from CNY 1,179,159,459.26, reflecting the impact of lower profits[9]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥167,416,992.51, an increase of 55.49% year-on-year[2]. - Cash inflow from operating activities for the current period is CNY 931,743,785.45, a decrease of 8.6% from CNY 1,019,533,563.96 in the previous period[13]. - Net cash flow from operating activities is CNY 167,416,992.51, an increase of 55.5% compared to CNY 107,671,521.85 in the previous period[13]. - Cash outflow from investing activities totals CNY 113,425,544.36, down from CNY 129,909,973.90 in the previous period, indicating a reduction of approximately 12.7%[14]. - Net cash flow from investing activities is -CNY 73,344,448.47, an improvement from -CNY 129,909,973.90 in the previous period[14]. - Cash inflow from financing activities is CNY 52,031,130.24, compared to CNY 153,069,467.36 in the previous period, reflecting a decrease of about 66%[14]. - Net cash flow from financing activities is -CNY 132,850,028.08, a significant decline from CNY 8,659,874.34 in the previous period[14]. - The ending balance of cash and cash equivalents is CNY 165,347,932.24, down from CNY 195,157,019.37 in the previous period, indicating a decrease of approximately 15.3%[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 13,793, with a significant increase in cash and cash equivalents due to exchange rate fluctuations, showing a 321.35% increase from the beginning of the period[6]. - The top two shareholders, Li Xi and Chen Xinmin, each hold 30.12% of the shares, totaling 100,865,992 shares[6]. - The company has not reported any changes in the top 10 shareholders due to securities lending or borrowing activities[7]. - The company has a total of 10 shareholders holding more than 5% of the shares, with a combined ownership of 60.24%[6]. Operational Highlights - The company reported a significant increase in accounts payable, which rose by 365.92% to ¥88,717,670.68 due to an increase in bank drafts issued[5]. - The company experienced a 70.24% decrease in short-term borrowings, totaling ¥18,015,766.67, primarily due to repayments made during the period[5]. - The company recorded a 772.77% increase in credit impairment losses, amounting to ¥1,088,084.52, attributed to changes in the provision for accounts receivable impairment[5]. - The company received government subsidies totaling ¥6,052,349.90 during the reporting period, contributing positively to its financial performance[3]. - Accounts receivable decreased to ¥115,689,051.34 from ¥140,891,243.50, indicating a reduction of approximately 17.9%[7]. - Inventory increased to ¥448,646,911.18 from ¥415,454,527.96, reflecting an increase of about 7.9%[7]. - The total current assets decreased to ¥837,084,165.75 from ¥866,733,217.90, a decline of approximately 3.4%[7]. - Other receivables increased to ¥4,852,802.36 from ¥3,953,728.09, marking an increase of approximately 22.7%[7]. - The company has not disclosed any new strategies or significant developments in product or technology during this reporting period[6]. Research and Development - Research and development expenses increased to CNY 97,598,889.44 in Q3 2024, up from CNY 77,799,671.07 in Q3 2023, indicating a focus on innovation[10]. Audit Status - The company has not undergone an audit for the Q3 2024 report[15].